JP2005519905A - Ｄｎａの製剤 - Google Patents

Ｄｎａの製剤 Download PDF

Info

Publication number
JP2005519905A
JP2005519905A JP2003561574A JP2003561574A JP2005519905A JP 2005519905 A JP2005519905 A JP 2005519905A JP 2003561574 A JP2003561574 A JP 2003561574A JP 2003561574 A JP2003561574 A JP 2003561574A JP 2005519905 A JP2005519905 A JP 2005519905A
Authority
JP
Japan
Prior art keywords
dna
preparation according
pharmaceutical preparation
dna pharmaceutical
storage medium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003561574A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005519905A5 (cg-RX-API-DMAC10.html
Inventor
キャッチポール，イアン，リチャード
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0201735A external-priority patent/GB0201735D0/en
Priority claimed from GBGB0201736.6A external-priority patent/GB0201736D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of JP2005519905A publication Critical patent/JP2005519905A/ja
Publication of JP2005519905A5 publication Critical patent/JP2005519905A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2003561574A 2002-01-25 2003-01-23 Ｄｎａの製剤 Pending JP2005519905A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0201735A GB0201735D0 (en) 2002-01-25 2002-01-25 DNA dosage forms
GBGB0201736.6A GB0201736D0 (en) 2002-01-25 2002-01-25 DNA dosage forms
PCT/GB2003/000336 WO2003061629A2 (en) 2002-01-25 2003-01-23 Dna dosage forms

Publications (2)

Publication Number Publication Date
JP2005519905A true JP2005519905A (ja) 2005-07-07
JP2005519905A5 JP2005519905A5 (cg-RX-API-DMAC10.html) 2006-02-09

Family

ID=27614803

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003561574A Pending JP2005519905A (ja) 2002-01-25 2003-01-23 Ｄｎａの製剤

Country Status (8)

Country Link
US (2) US20050085434A1 (cg-RX-API-DMAC10.html)
EP (1) EP1467711B1 (cg-RX-API-DMAC10.html)
JP (1) JP2005519905A (cg-RX-API-DMAC10.html)
AT (1) ATE357219T1 (cg-RX-API-DMAC10.html)
CA (1) CA2473717A1 (cg-RX-API-DMAC10.html)
DE (1) DE60312645T2 (cg-RX-API-DMAC10.html)
ES (1) ES2285087T3 (cg-RX-API-DMAC10.html)
WO (1) WO2003061629A2 (cg-RX-API-DMAC10.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007063265A (ja) * 2005-08-02 2007-03-15 Santen Pharmaceut Co Ltd 熱的に不安定な薬物の分解抑制方法
JP2011057717A (ja) * 2005-08-02 2011-03-24 Santen Pharmaceut Co Ltd イソプロピルウノプロストンの分解抑制方法

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7884083B2 (en) * 2002-08-12 2011-02-08 Dynavax Technologies Corporation Immunomodulatory compositions, methods of making, and methods of use thereof
AU2002951692A0 (en) * 2002-09-23 2002-10-17 Vital Biotech (Hong Kong) Limited Improvements in or relating to vaccines
GB0423681D0 (en) * 2004-10-26 2004-11-24 Sec Dep For Environment Food & Vaccine and nucleic acids
US8512679B2 (en) 2011-03-04 2013-08-20 Elwha Llc Glassy compositions

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08510639A (ja) * 1993-04-19 1996-11-12 メディソーブ・テクノロジーズ・インターナショナル・リミテッド・パートナーシップ 細胞取込みと遺伝子発現の促進と標的化をもたらす接合体と核酸のカプセル化
WO1997040839A1 (en) * 1996-04-26 1997-11-06 Merck & Co., Inc. Dna vaccine formulations
JP2001213807A (ja) * 1989-06-26 2001-08-07 Powderject Vaccines Inc 動物の体細胞の粒子媒介形質転換

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK28792D0 (da) * 1992-03-04 1992-03-04 Novo Nordisk As Nyt enzym
WO1995019799A1 (en) * 1994-01-21 1995-07-27 Agracetus, Inc. Gas driven gene delivery instrument
US6290991B1 (en) * 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
ATE252373T1 (de) * 1994-08-04 2003-11-15 Elan Drug Delivery Ltd Feste verabreichungssysteme zur gesteuerten freisetzung von darin eingebauten molekülen sowie verfahren zu deren herstellung

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001213807A (ja) * 1989-06-26 2001-08-07 Powderject Vaccines Inc 動物の体細胞の粒子媒介形質転換
JPH08510639A (ja) * 1993-04-19 1996-11-12 メディソーブ・テクノロジーズ・インターナショナル・リミテッド・パートナーシップ 細胞取込みと遺伝子発現の促進と標的化をもたらす接合体と核酸のカプセル化
WO1997040839A1 (en) * 1996-04-26 1997-11-06 Merck & Co., Inc. Dna vaccine formulations

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007063265A (ja) * 2005-08-02 2007-03-15 Santen Pharmaceut Co Ltd 熱的に不安定な薬物の分解抑制方法
JP2011057717A (ja) * 2005-08-02 2011-03-24 Santen Pharmaceut Co Ltd イソプロピルウノプロストンの分解抑制方法
JP2012140459A (ja) * 2005-08-02 2012-07-26 R Tec Ueno:Kk イソプロピルウノプロストンの分解抑制方法

Also Published As

Publication number Publication date
DE60312645T2 (de) 2007-11-29
US20080095854A1 (en) 2008-04-24
EP1467711B1 (en) 2007-03-21
ATE357219T1 (de) 2007-04-15
CA2473717A1 (en) 2003-07-31
WO2003061629A3 (en) 2003-10-02
EP1467711A2 (en) 2004-10-20
US20050085434A1 (en) 2005-04-21
WO2003061629A2 (en) 2003-07-31
ES2285087T3 (es) 2007-11-16
DE60312645D1 (de) 2007-05-03

Similar Documents

Publication Publication Date Title
EP1512429B1 (en) Needles coated with vaccine
JP2010534622A (ja) 抗原−アジュバント組成物および方法
US20020120228A1 (en) Powder compositions
EP1467720B1 (en) Dna dosage forms
HUT77777A (hu) Szilárd vivőrendszerek molekulák kontrollált kibocsátására és eljárások a vivőrendszerek előállítására
JP2004506020A (ja) 経口投与固形ワクチン
KR20140106389A (ko) 열안정성 백신 조성물 및 그의 제조방법
JP2003535119A (ja) 粉末組成物
US20080095854A1 (en) Dna dosage forms
EP1528914B1 (en) Antigenic compositions
US20050002969A1 (en) Binary composition for prime-boost release of active ingredients like vaccines
AU2001275371A1 (en) Powder compositions
HK1196265B (en) Thermostable vaccine compositions and methods of preparing same

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20051213

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20051213

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090203

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090427

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090508

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090723

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090915

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20091209

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20091216

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100525